The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Open accessAbstract
BACKGROUNDAlterations in the gene encoding fibroblast growth factor receptor (FGFR) are common in urothelial carcinoma and may be associated with lower sensitivity to immune interventions.Erdafitinib, a tyrosine kinase inhibitor of FGFR1-4, has shown antitumor activity in preclinical models and in a phase 1 study involving patients with FGFR alterations. METHODSIn this open-label, phase 2 study, we enrolled patients who had locally advanced and unresectable or metastatic urothelial carcinoma with prespecified FGFR alterations.All the patients had a history of disease progression during or after at least one course of chemotherapy or within 12 months after neoadjuvant or adjuvant chemotherapy.Prior immunotherapy was allowed.We initially randomly assigned the patients to receive erdafitinib in either an intermittent or a continuous regimen in the dose-selection phase of the study.On the basis of an interim analysis, the starting dose was set at 8 mg per day in a continuous regimen (selected-regimen group), with provision for a pharmacodynamically guided dose escalation to 9 mg.The primary end point was the objective response rate.Key secondary end points included progression-free survival, duration of response, and overall survival. RESULTSA total of 99 patients in the selected-regimen group received a median of five cycles of erdafitinib.Of these patients, 43% had received at least two previous courses of treatment, 79% had visceral metastases, and 53% had a creatinine clearance of less than 60 ml per minute.The rate of confirmed response to erdafitinib therapy was 40% (3% with a complete response and 37% with a partial response).Among the 22 patients who had undergone previous immunotherapy, the confirmed response rate was 59%.The median duration of progression-free survival was 5.5 months, and the median duration of overall survival was 13.8 months.Treatment-related adverse events of grade 3 or higher, which were managed mainly by dose adjustments, were reported in 46% of the patients; 13% of the patients discontinued treatment because of adverse events.There were no treatment-related deaths. CONCLUSIONSThe use of erdafitinib was associated with an objective tumor response in 40% of previously treated patients who had locally advanced and unresectable or metastatic urothelial carcinoma with FGFR alterations.Treatment-related grade 3 or higher adverse events were reported in nearly half the patients.(Funded by Janssen Research and Development; BLC2001 ClinicalTrials.govnumber, NCT02365597.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Self-citationPembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
Self-citationComprehensive molecular characterization of urothelial bladder carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/za09-dk57 · Cited by 2,990
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
Robertson, A. G., Kim, J., Al-Ahmadie, H., Bellmunt, J., Guo, G., Cherniack, A. D., Hinoue, T., Laird, P. W., Hoadley, K. A., Akbani, R., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.007 · Cited by 2,443
Sharma, P., Retz, M., Siefker-Radtke, A., Baron, A., Necchi, A., Bedke, J., Plimack, E. R., Vaena, D., Grimm, M.-O., Bracarda, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30065-7 · Cited by 1,736
Self-citationPowles, T., Durán, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U., Oudard, S., Retz, M. M., Castellano, D., Bamias, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33297-x · Cited by 1,408
Self-citationMolecular biology of bladder cancer: new insights into pathogenesis and clinical diversity
Knowles, M. A., & Hurst, C. D. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3817 · Cited by 1,247
Powles, T., O'Donnell, P. H., Massard, C., Arkenau, H.-T., Friedlander, T. W., Hoimes, C. J., Lee, J. L., Ong, M., Sridhar, S. S., Vogelzang, N. J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2411 · Cited by 869
Bellmunt, J., Théodore, C., Demkov, T., Komyakov, B., Sengelov, L., Daugaard, G., Caty, A., Carles, J., Jagiello-Gruszfeld, A., Karyakin, O., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5534 · Cited by 766
Cited by
Lenis, A. T., Lec, P. M., Chamie, K., & MSHS, M. (2020) · JAMA · doi:10.1001/jama.2020.17598 · Cited by 2,051
Witjes, J. A., Bruins, H. M., Cathomas, R., Compérat, E. M., Cowan, N. C., Gakis, G., Hernández, V., Linares Espinós, E., Lorch, A., Neuzillet, Y., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.03.055 · Cited by 2,017
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
Kamoun, A., de Reyniès, A., Allory, Y., Sjödahl, G., Robertson, A. G., Seiler, R., Hoadley, K. A., Groeneveld, C. S., Al-Ahmadie, H., Choi, W., et al. (2020) · European Urology · doi:10.1016/j.eururo.2019.09.006 · Cited by 1,359
Self-citationMosele, F., Remon, J., Mateo, J., Westphalen, C. B., Barlesi, F., Lolkema, M. P., Normanno, N., Scarpa, A., Robson, M., Meric-Bernstam, F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.014 · Cited by 1,186
Pascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J. D., Montagut, C., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.520 · Cited by 783
Alfred Witjes, J., Max Bruins, H., Carrión, A., Cathomas, R., Compérat, E., Efstathiou, J. A., Fietkau, R., Gakis, G., Lorch, A., Martini, A., et al. (2024) · European Urology · doi:10.1016/j.eururo.2023.08.016 · Cited by 648
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Flaig, T. W., Spiess, P. E., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., Chang, S., Downs, T. M., Efstathiou, J. A., Friedlander, T., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0011 · Cited by 626
Self-citationPowles, T., Kockx, M., Rodriguez-Vida, A., Duran, I., Crabb, S. J., Van Der Heijden, M. S., Szabados, B., Pous, A. F., Gravis, G., Herranz, U. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0628-7 · Cited by 591
Self-citationProperties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Roskoski, R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104609 · Cited by 559
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Powles, T., Bellmunt, J., Comperat, E., De Santis, M., Huddart, R., Loriot, Y., Necchi, A., Valderrama, B. P., Ravaud, A., Shariat, S. F., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2021.11.012 · Cited by 555
Self-citationTagawa, S. T., Balar, A. V., Petrylak, D. P., Kalebasty, A. R., Loriot, Y., Fléchon, A., Jain, R. K., Agarwal, N., Bupathi, M., Barthelemy, P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03489 · Cited by 543
Self-citationDyrskjøt, L., Hansel, D. E., Efstathiou, J. A., Knowles, M. A., Galsky, M. D., Teoh, J., & Theodorescu, D. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00468-9 · Cited by 544
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update
Rouprêt, M., Seisen, T., Birtle, A. J., Capoun, O., Compérat, E. M., Dominguez-Escrig, J. L., Gürses Andersson, I., Liedberg, F., Mariappan, P., Hugh Mostafid, A., et al. (2023) · European Urology · doi:10.1016/j.eururo.2023.03.013 · Cited by 525
Advances in diagnosis and treatment of bladder cancer
Lopez-Beltran, A., Cookson, M. S., Guercio, B. J., & Cheng, L. (2024) · BMJ · doi:10.1136/bmj-2023-076743 · Cited by 496
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
Huang, L., Jiang, S., & Shi, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00977-0 · Cited by 456
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 455
Current best practice for bladder cancer: a narrative review of diagnostics and treatments
Compérat, E., Amin, M. B., Cathomas, R., Choudhury, A., De Santis, M., Kamat, A., Stenzl, A., Thoeny, H. C., & Witjes, J. A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01188-6 · Cited by 435
Javle, M., Roychowdhury, S., Kelley, R. K., Sadeghi, S., Macarulla, T., Weiss, K. H., Waldschmidt, D.-T., Goyal, L., Borbath, I., El-Khoueiry, A., et al. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00196-5 · Cited by 428
Modulating extracellular matrix stiffness: A strategic approach to boost cancer immunotherapy
Mai, Z., Lin, Y., Lin, P., Zhao, X., & Cui, L. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-06697-4 · Cited by 398
From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
Nevala-Plagemann, C., Hidalgo, M., & Garrido-Laguna, I. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0281-6 · Cited by 393
Krook, M. A., Reeser, J. W., Ernst, G., Barker, H., Wilberding, M., Li, G., Chen, H.-Z., & Roychowdhury, S. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01157-0 · Cited by 363
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 341
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma
Loriot, Y., Matsubara, N., Park, S. H., Huddart, R. A., Burgess, E. F., Houede, N., Banek, S., Guadalupi, V., Ku, J. H., Valderrama, B. P., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308849 · Cited by 340
Self-citationThe 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma
Cathomas, R., Lorch, A., Bruins, H. M., Compérat, E. M., Cowan, N. C., Efstathiou, J. A., Fietkau, R., Gakis, G., Hernández, V., Espinós, E. L., et al. (2022) · European Urology · doi:10.1016/j.eururo.2021.09.026 · Cited by 295
Kato, S., Kim, K. H., Lim, H. J., Boichard, A., Nikanjam, M., Weihe, E., Kuo, D. J., Eskander, R. N., Goodman, A., Galanina, N., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18613-3 · Cited by 293
Sheng, X., Yan, X., Wang, L., Shi, Y., Yao, X., Luo, H., Shi, B., Liu, J., He, Z., Yu, G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2488 · Cited by 284
Silverman, I. M., Hollebecque, A., Friboulet, L., Owens, S., Newton, R. C., Zhen, H., Féliz, L., Zecchetto, C., Melisi, D., & Burn, T. C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0766 · Cited by 283
Personalized Medicine: Recent Progress in Cancer Therapy
Gambardella, V., Tarazona, N., Cejalvo, J. M., Lombardi, P., Huerta, M., Roselló, S., Fleitas, T., Roda, D., & Cervantes, A. (2020) · Cancers · doi:10.3390/cancers12041009 · Cited by 282
Bladder Cancer, Version 3.2024: Featured Updates to the NCCN Guidelines
Flaig, T. W., Spiess, P. E., Abern, M., Agarwal, N., Bangs, R., Buyyounouski, M. K., Chan, K., Chang, S. S., Chang, P., Friedlander, T., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0024 · Cited by 273
Self-citationProtein X-ray Crystallography and Drug Discovery
Maveyraud, L., & Mourey, L. (2020) · Molecules · doi:10.3390/molecules25051030 · Cited by 269
Meric-Bernstam, F., Bahleda, R., Hierro, C., Sanson, M., Bridgewater, J., Arkenau, H.-T., Tran, B., Kelley, R. K., Park, J. O., Javle, M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0697 · Cited by 258
Extracellular matrix stiffness: Mechanisms in tumor progression and therapeutic potential in cancer
Zhang, M., & Zhang, B. (2025) · Experimental Hematology & Oncology · doi:10.1186/s40164-025-00647-2 · Cited by 269
“In addition, specific proteins such as OPN play a key role in EGFR-TKI resistance by activating the integrin αVβ3/ FAK pathway in non-small cell lung cancer [75].”
FGFR-TKI resistance in cancer: current status and perspectives
Yue, S., Li, Y., Chen, X., Wang, J., Li, M., Chen, Y., & Wu, D. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01040-2 · Cited by 145
Xiong, J., Xiao, R., Zhao, J., Zhao, Q., Luo, M., Li, F., Zhang, W., & Wu, M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04810-3 · Cited by 79
Toward a More Precise Future for Oncology
Murciano-Goroff, Y. R., Taylor, B. S., Hyman, D. M., & Schram, A. M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.014 · Cited by 48
Identifying therapeutic targets for cancer among 2074 circulating proteins and risk of nine cancers
Smith-Byrne, K., Hedman, Å., Dimitriou, M., Desai, T., Sokolov, A. V., Schioth, H. B., Koprulu, M., Pietzner, M., Langenberg, C., Atkins, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46834-3 · Cited by 33
HER3 Alterations in Cancer and Potential Clinical Implications
Kilroy, M. K., Park, S., Feroz, W., Patel, H., Mishra, R., Alanazi, S., & Garrett, J. T. (2022) · Cancers · doi:10.3390/cancers14246174 · Cited by 21
Self-citationDe, S. K. (2023) · Medicines for Cancer · doi:10.1016/b978-0-443-13312-1.00009-x · Cited by 1
Metadata
- Authors
- Loriot, Y., Necchi, A., Park, S. H., Garcia-Donas, J., Huddart, R., Burgess, E., Fleming, M., Rezazadeh, A., Mellado, B., Varlamov, S., Joshi, M., Duran, I., Tagawa, S. T., Zakharia, Y., Zhong, B., Stuyckens, K., Santiago-Walker, A., De Porre, P., O’Hagan, A., Avadhani, A., & Siefker-Radtke, A. O.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-07-25
- Volume
- 381
- Issue
- 4
- Pages
- 338-348
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2964014383
- Cited by
- 1,360
- References
- 26
- FWCI
- 155.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.